Evaluation of convalescent plasma versus standard of care for the treatment of COVID-19 in hospitalized patients: study protocol for a phase 2 randomized, open-label, controlled, multicenter trial
Abstract Background COVID-19 is a respiratory disease caused by a novel coronavirus (SARS-CoV-2) and causes substantial morbidity and mortality. At the time this clinical trial was planned, there were no available vaccine or therapeutic agents with proven efficacy, but the severity of the condition prompted the use of several pharmacological and non-pharmacological interventions. It has long been hypothesized that the use of convalescent plasma (CP) from infected patients who have developed an effective immune response is likely to be an option for the treatment of patients with a variety of severe acute respiratory infections (SARI) of viral etiology. The aim of this study is to assess the efficacy and safety of convalescent plasma in adult patients with severe COVID-19 pneumonia. Methods/design The ConPlas-19 study is a multicenter, randomized, open-label controlled trial. The study has been planned to include 278 adult patients hospitalized with severe COVID-19 infection not requiring mechanical ventilation (invasive or non-invasive). Subjects are randomly assigned in a 1:1 ratio (139 per treatment arm), stratified by center, to receive intravenously administered CP (single infusion) plus SOC or SOC alone, and are to be followed for 30 days. The primary endpoint of the study is the proportion of patients that progress to category 5, 6, or 7 (on the 7-point ordinal scale proposed by the WHO) at day 15. Interim analyses for efficacy and/or futility will be conducted once 20%, 40%, and 60% of the planned sample size are enrolled and complete D15 assessment. Discussion This clinical trial is designed to evaluate the efficacy and safety of passive immunotherapy with convalescent plasma for the treatment of adult patients hospitalized with COVID-19. The results of this study are expected to contribute to establishing the potential place of CP in the therapeutics for a new viral disease. Trial registration ClinicalTrials.gov NCT04345523 . Registered on 30 March, 2020. First posted date: April 14, 2020..
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2021 |
|---|---|
| Erschienen: |
2021 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:22 |
|---|---|
| Enthalten in: |
Trials - 22(2021), 1, Seite 14 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Elena Diago-Sempere [VerfasserIn] |
|---|
| Links: |
doi.org [kostenfrei] |
|---|
| Themen: |
Antibodies |
|---|
| doi: |
10.1186/s13063-020-05011-9 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
DOAJ061830623 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | DOAJ061830623 | ||
| 003 | DE-627 | ||
| 005 | 20230309013959.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 230228s2021 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1186/s13063-020-05011-9 |2 doi | |
| 035 | |a (DE-627)DOAJ061830623 | ||
| 035 | |a (DE-599)DOAJ6132297c8d1646ecbb0de369893edf99 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 050 | 0 | |a R5-920 | |
| 100 | 0 | |a Elena Diago-Sempere |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Evaluation of convalescent plasma versus standard of care for the treatment of COVID-19 in hospitalized patients: study protocol for a phase 2 randomized, open-label, controlled, multicenter trial |
| 264 | 1 | |c 2021 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a Computermedien |b c |2 rdamedia | ||
| 338 | |a Online-Ressource |b cr |2 rdacarrier | ||
| 520 | |a Abstract Background COVID-19 is a respiratory disease caused by a novel coronavirus (SARS-CoV-2) and causes substantial morbidity and mortality. At the time this clinical trial was planned, there were no available vaccine or therapeutic agents with proven efficacy, but the severity of the condition prompted the use of several pharmacological and non-pharmacological interventions. It has long been hypothesized that the use of convalescent plasma (CP) from infected patients who have developed an effective immune response is likely to be an option for the treatment of patients with a variety of severe acute respiratory infections (SARI) of viral etiology. The aim of this study is to assess the efficacy and safety of convalescent plasma in adult patients with severe COVID-19 pneumonia. Methods/design The ConPlas-19 study is a multicenter, randomized, open-label controlled trial. The study has been planned to include 278 adult patients hospitalized with severe COVID-19 infection not requiring mechanical ventilation (invasive or non-invasive). Subjects are randomly assigned in a 1:1 ratio (139 per treatment arm), stratified by center, to receive intravenously administered CP (single infusion) plus SOC or SOC alone, and are to be followed for 30 days. The primary endpoint of the study is the proportion of patients that progress to category 5, 6, or 7 (on the 7-point ordinal scale proposed by the WHO) at day 15. Interim analyses for efficacy and/or futility will be conducted once 20%, 40%, and 60% of the planned sample size are enrolled and complete D15 assessment. Discussion This clinical trial is designed to evaluate the efficacy and safety of passive immunotherapy with convalescent plasma for the treatment of adult patients hospitalized with COVID-19. The results of this study are expected to contribute to establishing the potential place of CP in the therapeutics for a new viral disease. Trial registration ClinicalTrials.gov NCT04345523 . Registered on 30 March, 2020. First posted date: April 14, 2020. | ||
| 650 | 4 | |a COVID-19 | |
| 650 | 4 | |a Randomized | |
| 650 | 4 | |a Controlled trial | |
| 650 | 4 | |a Protocol | |
| 650 | 4 | |a Convalescent plasma (CP) | |
| 650 | 4 | |a Antibodies | |
| 653 | 0 | |a Medicine (General) | |
| 700 | 0 | |a José Luis Bueno |e verfasserin |4 aut | |
| 700 | 0 | |a Aránzazu Sancho-López |e verfasserin |4 aut | |
| 700 | 0 | |a Elena Múñez Rubio |e verfasserin |4 aut | |
| 700 | 0 | |a Ferrán Torres |e verfasserin |4 aut | |
| 700 | 0 | |a Rosa Malo de Molina |e verfasserin |4 aut | |
| 700 | 0 | |a Ana Fernández-Cruz |e verfasserin |4 aut | |
| 700 | 0 | |a Isabel Salcedo de Diego |e verfasserin |4 aut | |
| 700 | 0 | |a Ana Velasco-Iglesias |e verfasserin |4 aut | |
| 700 | 0 | |a Concepción Payares-Herrera |e verfasserin |4 aut | |
| 700 | 0 | |a Inmaculada Casas Flecha |e verfasserin |4 aut | |
| 700 | 0 | |a Cristina Avendaño-Solà |e verfasserin |4 aut | |
| 700 | 0 | |a Rafael Duarte Palomino |e verfasserin |4 aut | |
| 700 | 0 | |a Antonio Ramos-Martínez |e verfasserin |4 aut | |
| 700 | 0 | |a Belén Ruiz-Antorán |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i In |t Trials |d BMC, 2006 |g 22(2021), 1, Seite 14 |w (DE-627)DOAJ000057452 |x 17456215 |7 nnns |
| 773 | 1 | 8 | |g volume:22 |g year:2021 |g number:1 |g pages:14 |
| 856 | 4 | 0 | |u https://doi.org/10.1186/s13063-020-05011-9 |z kostenfrei |
| 856 | 4 | 0 | |u https://doaj.org/article/6132297c8d1646ecbb0de369893edf99 |z kostenfrei |
| 856 | 4 | 0 | |u https://doi.org/10.1186/s13063-020-05011-9 |z kostenfrei |
| 856 | 4 | 2 | |u https://doaj.org/toc/1745-6215 |y Journal toc |z kostenfrei |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_DOAJ | ||
| 951 | |a AR | ||
| 952 | |d 22 |j 2021 |e 1 |h 14 | ||